SuperworthOruka Therapeutics shares outstanding ORKA
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 62.9M
- On a year earlier
- +49.4%
- more shares
Oruka Therapeutics had 62.9M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 49.4% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 54.5M | +4431% |
| FY2023 | 1.2M | +0% |
| FY2022 | 1.2M | +0% |
| FY2021 | 1.2M | +54% |
| FY2020 | 778.6K | +486% |
| FY2019 | 132.8K | +106% |
| FY2018 | 64.5K | +18% |
| FY2017 | 54.5K | +30% |
| FY2016 | 42K | +0% |
| FY2015 | 41.9K | +200% |
| FY2014 | 14K | +36% |
| FY2013 | 10.3K | +509% |
| FY2012 | 1.7K | +43% |
| FY2011 | 1.2K | +21% |
| FY2010 | 972 | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 62.9M | +49% | |
| Q1 FY26 | 55.2M | +32% | |
| Q4 FY25 | 54.5M | n/a | |
| Q3 FY25 | 44.1M | +194% | |
| Q2 FY25 | 42.1M | +1216% | |
| Q1 FY25 | 41.7M | +3349% | |
| Q3 FY24 | 15M | +1150% | |
| Q2 FY24 | 3.2M | +166% | |
| Q1 FY24 | 1.2M | +1% | |
| Q4 FY23 | 1.2M | +0% | |
| Q3 FY23 | 1.2M | +0% | |
| Q2 FY23 | 1.2M | +0% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Oruka Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.